An interventional study of Attentional Bias Modification Treatment (ABMT) - Active and Attentional Bias Modification Treatment - Placebo in Generalized Anxiety Disorder, Separation Anxiety Disorder and Social Anxiety Disorder, sponsored by Hospital de Clinicas de Porto Alegre. Status unknown at 4 sites in 4 countries. Open to participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-09-19.
Sponsored by Hospital de Clinicas de Porto Alegre · Not applicable, Interventional, and Treatment
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 115th largest by planned enrollment of the 234 interventional ones that give a count, is one of 6 that started in 2011, is one of 122 with no phase, and was the 100th registered.
517 studies on the registry are indexed under Generalized Anxiety Disorder; 124 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Intra-Cellular Therapies, Inc. · Sites in United States
BTL Industries Ltd. · Sites in United States
Intra-Cellular Therapies, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 7 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 6 started in 2011.
This study's planned enrollment of 90 is close to the median of 83 across 439 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
Hospital de Clinicas de Porto Alegre is the lead sponsor of 456 studies on the registry; 61 are open to participants now.
Hospital de Clinicas de Porto Alegre has 4 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this project is to test the combination of active or placebo Attentional Bias Modification Treatment (ABMT) to either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for anxiety disorders in children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Attentional Bias Modification Treatment (ABMT) - Active · Behavioral: Cognitive Behavioral Group Therapy
Other: Attentional Bias Modification Treatment - Placebo · Behavioral: Cognitive Behavioral Group Therapy
Other: Attentional Bias Modification Treatment (ABMT) - Active · Behavioral: Psychoeducational Control Intervention
Other: Attentional Bias Modification Treatment - Placebo · Behavioral: Psychoeducational Control Intervention
The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
"FRIENDS for Life" Australian protocol for the treatment of anxiety disorders in children
Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
Pediatric Anxiety Rating Scale (PARS) / continuous
Score change on Pediatric Anxiety Rating Scale (PARS) from baseline to week 10 and to 6-month follow-up
Time frame: Endpoint (week 10) and 6-month follow-up
Clinical Global Impression - Improvement Scale (CGI-I) / dichotomous
Percentage of subjects with less than 2 points in the CGI-I scale in week 10 and in 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
Screen for Children and Anxiety Related Emotional Disorders (SCARED)
Score change in SCARED child and parent versions from baseline to week 10 and 6-months follow-up
Time frame: Endpoint (week-10) and 6-months follow-up
Childhood Depression Inventory (CDI)
Score change in CDI from baseline to week-10 and to 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
Swanson, Nolan, and Pelham scale - Version IV (SNAP-IV)
Score change in SNAP-IV from baseline to week-10 and 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
Spence Children's Anxiety Scale (SCAS)
Score change in SCAS from baseline to week-10 and to 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
Neuropsychological measures
Change in neuropsychological measures from baseline to week-10 and 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
Biological measures
Change in biological measures from baseline to week-10 and to 6-month follow-up
Time frame: Endpoint (week-10) and 6-month follow-up
The record gives a start of Aug 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
Hospital de Clinicas de Porto Alegre →